5 June 2023
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Director/PDMR Dealing
Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, has been notified that Dr Adam Mark Hill, PDMR and Chief Executive Officer, today purchased 48,370 ordinary shares of £0.01 each in the Company ("Ordinary Shares") at a price of £0.206533 per share.
Following this transaction, Dr Hill has a total interest in the Company of 122,242 Ordinary Shares, representing approximately 0.17 per cent. of the Company's issued share capital of 74,142,147.
In addition, Dr Hill holds options over a total of 3,615,862 Ordinary Shares, representing approximately 4.88 per cent. of the Company's issued share capital.
This announcement, including the notification below, is made in accordance with the requirements of Article 19 of the UK Market Abuse Regulation.
Notification and public disclosure of transactions by person discharging managerial responsibilities and persons closely associated with them:
| 1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
| a)
| Name
| Dr Adam Mark Hill | |||
| 2
| Reason for the notification
| ||||
| a)
| Position/status
| Chief Executive Officer | |||
| b)
| Initial notification /Amendment
| Initial Notification | |||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
| a)
| Name
| Oncimmune Holdings plc | |||
| b)
| LEI
| 213800HCYIWT6YPI1I02 | |||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
| a)
| Description of the financial instrument, type of instrument | Ordinary Shares of £0.01 each | |||
| | | ||||
| Identification code | ISIN: GB00BYQ94H38 | ||||
| | | ||||
| b)
| Nature of the transaction
| Purchase of Ordinary Shares | |||
| c)
| Price(s) and volume(s) | | | | |
| | | Price(s) | Volume(s) | | |
| | | £0.206533 | 48,370 | | |
| | | | | | |
| d)
| Aggregated information | N/A - single transaction | |||
| | | ||||
| - Aggregated volume | | ||||
| | | ||||
| - Price | | ||||
| | | ||||
| e)
| Date of the transaction | 5 June 2023 | |||
| f) | Place of the transaction | London Stock Exchange, AIMX
| |||
For further information:
Oncimmune Holdings plc
Dr Adam M Hill, Chief Executive Officer
Matthew Hall, Chief Financial Officer
Singer Capital Markets (Nominated Adviser and Broker)
Phil Davies, Harry Gooden, George Tzimas, James Fischer
+44 (0)20 7496 3000
Zeus (Joint Broker)
Dominic King, Victoria Ayton, Dan Bate
+44 (0)20 3829 5000
About Oncimmune
Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. The ImmunoINSIGHTS service business leverages Oncimmune's technology platform and methodologies across multiple diseases, to offer life-science organizations actionable insights for therapies across the development and product lifecycle. Our core immune-profiling technology is underpinned by our library of over eight thousand immunogenic proteins, one of the largest of its kind. This helps identify trial participants and patients into clinically relevant subgroups, enabling development of targeted and more effective treatments.
Oncimmune's ImmunoINSIGHTS service business is based at the Company's discovery research centre in Dortmund, Germany. The business platform enables life science organizations to optimize drug development and delivery, leading to more effectively targeted and safer treatments for patients.
The ImmunoINSIGHTS development team is based in the US and Europe and Oncimmune is seeking to replicate the Dortmund facility in the US in the medium term.
For more information, visit www.oncimmune.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.